Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Adagene Inc. (Nasdaq: ADAG) has announced upcoming poster presentations at the SITC 39th Annual Meeting in Houston, scheduled for November 6-10, 2024. The presentations will focus on Muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody®.
Two posters will be presented on November 9:
Abstract 506: Comparing the clinical therapeutic index of Muzastotug to its unmasked form (ADG116) as monotherapy or combined with anti-PD-1 therapy. Abstract 744: Phase 1b/2 study of Muzastotug combined with Pembrolizumab in advanced/metastatic MSS CRCs. Both posters will be viewable during lunch (12:15-1:45 PM CST) and at the poster reception (7:10-8:30 PM CST) at the George R. Brown Convention Center. The posters will also be available on
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more